Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics’ RheOx™ System for Chronic Bronchitis

SAN CARLOS, Calif.: SAN CARLOS, Calif., Aug. 31, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced new data from multiple clinical studies that demonstrate improvements in chronic bronchitis symptoms after patients received bronchial rheoplasty therapy using Gala's first-of-its kind, endoscopic...

Click to view original post